Indirect comparison studies - are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation

Thrombosis and Haemostasis

Volumn 108, Issue 3, 2012, Pages 405-406

  Skjøth, Flemming ^a   Larsen, Torben Bjerregaard ^a,b   Rasmussen, Lars Hvilsted ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

BLEEDING; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; THROMBOPHILIA;

EID: 84865832312     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-06-0438     Document Type: Editorial

References (17)

1. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106:1012-1019.
2. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104:49-60.
3. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011; 105:574-578.
4. Mantha S, Ansel J. An Indirect Comparison of Dabigatran, Rivaroxaban and Apixaban for Atrial Fibrillation. Thromb Haemost 2012; 108:476-484.
5. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart I 2012; 163: 13-19.
6. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
7. Lip GYH, Larsen TB, Skjoth F, et al. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol 2012; epub ahead of print.
8. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. Br Med J 2009; 338: 1147-1154.
9. Edwards S J, Clarke M J, Wordsworth S, et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009; 63: 841-854.
10. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2011; 105: 1-10.
11. Jansen JP, Fleurence R, Devine B, et al. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1.Value Health 2011; 14:417-428.
12. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.
13. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=l. Thromb Haemost 2010; 103:833-840.
14. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
15. Karthikeyan G, Eikelboom JW The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost 2010; 104: 45-48.
16. Keogh C.Wallace E, Dillon C, et al. Validation of the CHADS2 clinical prediction rule to predict is-chaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
17. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.